Li-Anne Rowswell Mufson 9/14/26 Li-Anne Rowswell Mufson 9/14/26

High Cholesterol Gone with One Treatment?

Li-Anne Rowswell Mufson 8/31/26 Li-Anne Rowswell Mufson 8/31/26

In Vivo CAR-T Cell Therapy: Rewriting the Rules of Cancer Treatment

Li-Anne Rowswell Mufson 4/13/26 Li-Anne Rowswell Mufson 4/13/26

The Real Stakes of Phase 2: You Cannot Afford to Wait

Phase 2 is the ultimate "make or break" moment for drug development and why cutting corners now leads to catastrophic failure later. This Guard Rail blog breaks down the essential risk-mitigation strategies needed to bridge the treacherous gap between initial proof of concept and a successful Phase 3 trial.

Li-Anne Rowswell Mufson 3/30/26 Li-Anne Rowswell Mufson 3/30/26

The Australian Advantage in Early Stage Clinical Trials

Amanda Sicard 3/9/26 Amanda Sicard 3/9/26

From Academic Discovery to Clinical Trials: Transitional Priorities

Moving a drug from academic discovery to clinical trials is one of the most critical phases in pharmaceutical development. Academic research often focuses on understanding disease mechanisms and identifying potential targets

High Cholesterol Gone with One Treatment?

In Vivo CAR-T Cell Therapy: Rewriting the Rules of Cancer Treatment

The Real Stakes of Phase 2: You Cannot Afford to Wait

The Australian Advantage in Early Stage Clinical Trials

From Academic Discovery to Clinical Trials: Transitional Priorities

Social Media

Message Us

Contact Us